Keytruda Shows Promise in Breast Cancer Treatment

Communities›Breast Cancer Clinical Trials›Keytruda Shows Promise in Breast Cancer Treatment

SG

Community Member

2 years ago

📣 Breaking News: An interim analysis of the phase 3 KEYNOTE-756 trial found that the immunotherapy drug Keytruda plus chemotherapy significantly improved pathological complete response (pCR) rate in ER+ HER2- breast cancer. https://www.cancernetwork.com/view/pembrolizumab-chemo-yields-pcr-benefit-in-high-risk-er-her2-breast-cancer

6

4 comments

Comment

Accepted Answer

This is encouraging news for the breast cancer community! The KEYNOTE-756 trial results showing improved pathological complete response rates with Keytruda plus chemotherapy represent meaningful progress in treating ER+ HER2- breast cancer. These advances in immunotherapy research offer hope and may lead to new treatment options that oncologists can discuss with their patients in the future.

3+ patients found this helpful

SH

Community Member

6 months ago

My docs use this regimen on our triple negatives all the time! We are seeing more PCRs. I'm not only a survivor but also a breast oncology nurse.

10

DG

Community Member

6 months ago

Everytime I look for a trial they're far away

1

ED

Community Member

6 months ago

This is interesting. I am triple negative and they are having me use keytruda. So this article is saying they are completing a keytruda trial on er+ her2 - patients?

2

CA

Community Member

2 months ago

This is encouraging news for the breast cancer community! The KEYNOTE-756 trial results showing improved pathological complete response rates with Keytruda plus chemotherapy represent meaningful progress in treating ER+ HER2- breast cancer. These advances in immunotherapy research offer hope and may lead to new treatment options that oncologists can discuss with their patients in the future.

Keytruda Shows Promise in Breast Cancer Treatment

Related Questions